Overview

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Catabasis Pharmaceuticals

Treatments:

Atorvastatin
Atorvastatin Calcium